NTLA Quote, Financials, Valuation and Earnings

Pacific Biosciences of California, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of -90.43%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Pacific Biosciences of California, Inc.'s return on equity of -389.62%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 82.95%. On the other hand Pacific Biosciences of California, Inc. has an analysts' consensus of $2.50 which suggests that it could grow by 48.81%. Given that Intellia Therapeutics, Inc. has higher upside potential than Pacific Biosciences of California, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Pacific Biosciences of California, Inc..

Intellia Therapeutics, Inc. has a beta of 2.103, which suggesting that the stock is 110.271% more volatile than S&P 500. In comparison Pacific Biosciences of California, Inc. has a beta of 2.267, suggesting its more volatile than the S&P 500 by 126.686%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pacific Biosciences of California, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Pacific Biosciences of California, Inc. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Pacific Biosciences of California, Inc. quarterly revenues of $44.6M. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Pacific Biosciences of California, Inc.'s net income of -$40.4M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Pacific Biosciences of California, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 23.76x versus 3.15x for Pacific Biosciences of California, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Personalis, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of -149.38%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Personalis, Inc.'s return on equity of -39.33%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 82.95%. On the other hand Personalis, Inc. has an analysts' consensus of $11.29 which suggests that it could grow by 26.66%. Given that Intellia Therapeutics, Inc. has higher upside potential than Personalis, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Personalis, Inc..

Intellia Therapeutics, Inc. has a beta of 2.103, which suggesting that the stock is 110.271% more volatile than S&P 500. In comparison Personalis, Inc. has a beta of 1.980, suggesting its more volatile than the S&P 500 by 97.958%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Personalis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Personalis, Inc. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Personalis, Inc. quarterly revenues of $14.5M. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Personalis, Inc.'s net income of -$21.7M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Personalis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 23.76x versus 10.88x for Personalis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of 21.74%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 14.93%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 82.95%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $868.04 which suggests that it could grow by 10.95%. Given that Intellia Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Intellia Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Intellia Therapeutics, Inc. has a beta of 2.103, which suggesting that the stock is 110.271% more volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.398, suggesting its less volatile than the S&P 500 by 60.232%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.94 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out 8.49% of its earnings as a dividend. Regeneron Pharmaceuticals, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.9B. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $844.6M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.82x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 23.76x versus 5.93x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Twist Bioscience Corp. has a net margin of -735.19% compared to Intellia Therapeutics, Inc.'s net margin of -29.42%. Intellia Therapeutics, Inc.'s return on equity of -54.66% beat Twist Bioscience Corp.'s return on equity of -16.63%.

Intellia Therapeutics, Inc. has a consensus price target of $23.86, signalling upside risk potential of 82.95%. On the other hand Twist Bioscience Corp. has an analysts' consensus of $49.89 which suggests that it could fall by -4.96%. Given that Intellia Therapeutics, Inc. has higher upside potential than Twist Bioscience Corp., analysts believe Intellia Therapeutics, Inc. is more attractive than Twist Bioscience Corp..

Intellia Therapeutics, Inc. has a beta of 2.103, which suggesting that the stock is 110.271% more volatile than S&P 500. In comparison Twist Bioscience Corp. has a beta of 2.240, suggesting its more volatile than the S&P 500 by 124.046%.

Intellia Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Twist Bioscience Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Intellia Therapeutics, Inc. pays -- of its earnings as a dividend. Twist Bioscience Corp. pays out -- of its earnings as a dividend.

Intellia Therapeutics, Inc. quarterly revenues are $13.8M, which are smaller than Twist Bioscience Corp. quarterly revenues of $103.7M. Intellia Therapeutics, Inc.'s net income of -$101.3M is lower than Twist Bioscience Corp.'s net income of -$30.5M. Notably, Intellia Therapeutics, Inc.'s price-to-earnings ratio is -- while Twist Bioscience Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Intellia Therapeutics, Inc. is 23.76x versus 8.12x for Twist Bioscience Corp.. Usually stocks with elevated PS ratios are considered overvalued.